Table 13.

Overview of identification of diffraction peaks for polymorphs.

#	Sample	Polymorph Identification	Characteristic Peaks (° 2θ)	Ref.
1P	Ranitidine hydrochloride *	Form 1	17, 21.8, 24.9	[74]
		Form 2	20.40, 23.7
2P	Chlorhexidine dihydrochloride *	Form 1 → initial spectrum	13.9, 18.5, 23.7	[140]
		Form 2 → few peaks	5.2
		Form 3 → many Bragg peaks	14.9, 28.3
3P	γ-Sorbitol *	A phase → Sharp peaks, increased milling time	16.6, 30.9	[34]
		γ phase	11.6, 25.5
4P	Rivastigmine	Form II	9.5, 11.3, 14.2, 15.5, 19.1, 20	[141]
		Form I → Broadeneing of peaks	5.1, 14.7, 16.5, 17.6, 18.6, 20.4, 21.1
5P	o-Aminobenzoic acid	FI	10.7, 13.7, 14.35, 16.4, 18.6, 23.5, 24.3, 24.9, 26.2, 27.6, 30.5	[54]
		FII	11.2, 15.4, 22.2, 26.7
	m-Aminobenzoic acid (FIII form)	FI	8.6, 17.2, 24.9
		FIII	8.3, 16.8, 17.9, 23.7, 23.7, 24.2, 25.9, 26.6, 27.8
	p-aminobenzoic acid	β-form	17.2, 17.6, 20, 21.9, 25.5, 27.9
		α-PABA	17.1, 19.9, 21.8, 25.3, 27.8
6P	Dexamethasone *	Form A	7.9, 13.5, 16.0, 17.6	[27]
		Form B	7.5, 16.8, 18.4
7P	Sofosbuvir *	Form I	5.3, 7.6, 9.0, 9.8, 10.3	[79]
		Form A	6.2, 8.4, 10.5, 12.8,17.4, 17.9, 18.2, 20.3, 21.1
		Form B	7.9, 10.3, 12.3, 16.7, 17.1, 19.3, 20, 20.9
		Form V	5.6, 6.9, 7.5, 10, 10.8, 13.8, 16.4, 19.7, 25.4
8P	Sulindac *	Form I	10.8, 17.6	[69]
		Form II	9.3, 16.1
9P	Γ-sorbitol *	Γ-form	11.7, 25.6	[75]
		A-Form	16.7, 31.1
12P	Sulfamerazine	I	12.6, 14.8, 16.3, 17.4, 20.5, 22.7, 23, 24.6, 31.2, 32.7	[166]
		II	14.5, 17.0, 19.2, 21.5, 26.6, 27.4, 27.9